Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) will present and host one-on-one meetings at Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston on Nov. 10, 2026. President and CEO Seth Lederman, M.D., will deliver the company presentation from 4 to 4:25 p.m. ET, with a live webcast and replay available under the News & Events tab in the Investors section of the company's website.
The presentation matters because Tonix is a fully integrated, commercial-stage biopharmaceutical company whose recent approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) marks the first new treatment for fibromyalgia in more than 15 years. That milestone gives the company a flagship commercial product and a platform to expand its central nervous system franchise. Investors will likely focus on early launch metrics and the broader commercial infrastructure supporting TONMYA and Tonix's acute migraine products, Zembrace SymTouch and Tosymra.
Beyond its marketed products, Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. The company's CNS portfolio also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. All development candidates remain investigational, and their efficacy and safety have not been established or approved for any indication.
For readers and industry observers, the conference appearance is a chance to assess how Tonix is balancing a commercial launch with a pipeline that spans CNS and immunology. The fibromyalgia approval addresses a market that had gone more than 15 years without a new treatment, so execution on the TONMYA rollout could influence how the company funds its Phase 2 and later-stage programs. Full details are available in the company's press release at https://ibn.fm/f7udM, and the latest updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
The announcement was distributed through InvestorWire, a specialized communications platform focused on wire-grade press release syndication for private and public companies and the investment community. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which also provides editorial syndication to 5,000+ outlets, press release enhancement and social media distribution via IBN, along with tailored corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
